4284-47-3

Upstream product

• 106-49-0 p-toluidine 
• 124-63-0 methanesulfonyl chloride 
• 54378-81-3 C₂₇H₂₆NO₄PS₂ 
• 3144-09-0 methanesulfonamide 
• 106-38-7 para-bromotoluene 
• 106-44-5 p-cresol 
• 106-43-4 para-chlorotoluene 
• 93131-73-8 4-tolyl perfluorobutanesulfonate 
• 5720-05-8 4-methylphenylboronic acid 
• 624-90-8 Methanesulfonyl azide 
• 624-31-7 4-tolyl iodide 
• 99-99-0 1-methyl-4-nitrobenzene 
• 20277-69-4 sodium methansulfinate 

Downstream Products

• 109495-72-9 N-(2-chloro-4-methylphenyl)methanesulfonamide 
• 114723-63-6 methanesulfonic acid-(2,3,5,6-tetrachloro-4-methyl-anilide) 
• 22729-82-4 N-(1,1,2,2-Tetrachloro-2-fluoro-ethylsulfanyl)-N-p-tolyl-methanesulfonamide 
• 108297-29-6 N-(4-Methyl-2-pyrrolidin-1-ylmethyl-phenyl)-methanesulfonamide 
• 88131-57-1 N-(3,3-Diethoxy-propyl)-N-p-tolyl-methanesulfonamide 
• 88131-49-1 N-(2,2-Diethoxy-ethyl)-N-p-tolyl-methanesulfonamide 
• 4284-63-3 2-Methanesulfonyl-4-methyl-phenylamine 
• 265995-45-7 N-(4-methylphenyl)-2-hydroxyethanesulfonamide 
• 333383-71-4 N-(3-oxo-propyl)-N-p-tolyl-methanesulfonamide 
• 91-62-3 6-methylquinoline 
• 265995-37-7 N-(4-methylphenyl)-1,2-thiazetidine 1,1-dioxide 
• 265995-51-5 N-(4-methylphenyl)-2-hydroxyethanesulfonamide mesylate 
• 10355-06-3 methyl 3-methylphenyl sulfone 
• 1188925-34-9 N-(4-methoxy-4-methylcyclohexa-2,5-dien-1-ylidene)methanesulfonamide 

Relevant academic research and scientific papers

Ultrasound-assisted one-pot three-component synthesis of new isoxazolines bearing sulfonamides and their evaluation against hematological malignancies

In the present study, following a one-pot two-step protocol, we have synthesized novel sulfonamides-isoxazolines hybrids (3a-r) via a highly regioselective 1,3-dipolar cycloaddition. The present methodology capitalized on trichloroisocyanuric acid (TCCA) as a safe and ecological oxidant and chlorinating agent for the in-situ conversion of aldehydes to nitrile oxides in the presence of hydroxylamine hydrochloride, under ultrasound activation. These nitrile oxides could be engaged in 1,3-dipolar cycloaddition reactions with various alkene to afford the targeted sulfonamides-isoxazolines hybrids (3a-r). The latter were assessed for their antineoplastic activity against model leukemia cell lines (Chronic Myeloid Leukemia, K562 and Promyelocytic Leukemia, HL-60).

Metal-free synthesis of biaryls from aryl sulfoxides and sulfonanilides via sigmatropic rearrangement

Treatment of aryl sulfoxides and sulfonanilides with trifluoroacetic anhydride resulted in the dehydrative metal-free construction of the corresponding unsymmetrical biaryls. The reaction would proceed via (1) the activation of aryl sulfoxide with the anhydride, (2) interrupted Pummerer reaction of the resulting arylsulfonium with sulfonanilide, (3) [3,3] sigmatropic rearrangement to cleave the transient S–N bond and to form the prospective biaryl C–C bond, and (4) global aromatization. The choice of the amino protecting group is crucial, and only N-sulfonylanilines, i.e., sulfonanilides, could participate in the formation of biaryls.

Copper-catalyzed redox coupling of nitroarenes with sodium sulfinates

A simple copper-catalyzed redox coupling of sodium sulfinates and nitroarenes is described. In this process, abundant and stable nitroarenes serve as both the nitrogen sources and oxidants, and sodium sulfinates act as both reactants and reductants. A variety of aromatic sulfonamides were obtained in moderate to good yields with broad substrate scope. No external additive is employed for this kind of transformation.

Facile Chan-Lam coupling using ferrocene tethered N-heterocyclic carbene-copper complex anchored on graphene

Ferrocene tethered N-heterocyclic carbene-copper complex anchored on graphene ([GrFemImi]NHC@Cu complex) has been synthesized by covalent grafting of ferrocenyl ionic liquid in the matrix of graphene followed by metallation with copper (I) iodide. The [GrFemImi]NHC@Cu complex has been characterized by fourier transform infrared (FT-IR), fourier transform Raman (FT-Raman), CP-MAS 13C NMR spectroscopy, transmission electron microscopy (TEM), thermogravimetric analysis (TGA), energy dispersive X-ray (EDX) analysis, X-ray photoelectron spectroscopy (XPS), Brunauer–Emmett–Teller (BET) surface area analysis and X-ray diffractometer (XRD) analysis. This novel complex served as a robust heterogeneous catalyst for the synthesis of bioactive N-aryl sulfonamides from variety of aryl boronic acids and sulfonyl azides in ethanol by Chan-Lam coupling. Recyclability experiments were executed successfully for six consecutive runs.

Continuous-Flow Electrosynthesis of Benzofused S-Heterocycles by Dehydrogenative C?S Cross-Coupling

Reported herein is the synthesis of benzofused six-membered S-heterocycles by intramolecular dehydrogenative C?S coupling using a modular flow electrolysis cell. The continuous-flow electrosynthesis not only ensures efficient product formation, but also obviates the need for transition-metal catalysts, oxidizing reagents, and supporting electrolytes. Reaction scale-up is conveniently achieved through extended electrolysis without changing the reaction conditions and equipment.

Ligand-Enabled Gold-Catalyzed C(sp2)-N Cross-Coupling Reactions of Aryl Iodides with Amines

The first example of ancillary (P,N)-ligand-enabled gold-catalyzed C-N cross-coupling reactions of aryl iodides with amines is reported. The high generality of the reaction in de novo synthesis, late-stage modifications, and cascade processes to access functionalized indolinones and carbazoles underscores the synthetic potential of the presented strategy. Monitoring the reaction with ESI-HRMS and NMR provided strong evidence for the in situ formation of putative high valent Au(III) intermediates.

Soft-Hard Acid/Base-Controlled, Oxidative, N-Selective Arylation of Sulfonanilides via a Nitrenium Ion

In iodine(III)-catalyzed, dehydrogenative arylations of sulfonanilides, the functionalization of C-C bonds is preferred over the functionalization of C-N bonds. Herein, an unprecedented N-selective arylation of sulfonanilides using soft-hard acid-base (SHAB) control by a nitrenium ion over a carbenium ion is reported. Treatment of sulfonanilides with iodine(III) led to the formation of nitrenium ions (soft), which preferentially react with biphenyls (soft) over bimesityl (hard) to generate C-N bonds. The iodine(III) was generated in situ by using PhI and mCPBA at room temperature.

Synthesis of CF3CH2-Containing Indolines by Transition-Metal-Free Aryltrifluoromethylation of Unactivated Alkenes

With an unactivated double bond as the radical acceptor, allyl amines underwent a metal-free trifluoromethylation/cyclization cascade with CF3SO2Na (Langlois' reagent), affording CF3CH2-containing indolines and tetrahydroisoquinolines, whose practical syntheses are significant challenges. This protocol features mild conditions, low cost, and a broad substrate scope.

Synthetic method of CF3-containing indoline and 1,2,3,4-tetrahydroisoquinoline

The invention discloses a synthetic method of CF3-containing indoline and 1,2,3,4-tetrahydroisoquinoline and relates to the technical field of compound synthesis. The synthetic method herein is basedon metal-free trifluoromethylation/cyclization free radical cascade reaction using a nonactive olefin dual-bond as a free radical receptor; the reaction aforementioned helps synthesize, in one step, CF3-containing indoline and 1,2,3,4-tetrahydroisoquinoline. The synthetic method herein has the significant advantages of mild conditions, good operational simplicity, low cost, wide substrate range, good exo selectivity and the like.

Novel substituted sulfamide compound, preparation method and application thereof as PTP1B inhibitor

The invention relates to a novel substituted sulfamide compound of a structure of a formula I as shown in the description, a pharmaceutically acceptable salt of the novel substituted sulfamide compound, a preparation method, and relates to a medicinal composition comprising the compound of the formula I or a pharmaceutically acceptable salt of the compound. The compound of the formula I or the pharmaceutically acceptable salt of the compound has activity of inhibiting protein tyrosine phosphatase 1B (PTP1B), so that the compound or the pharmaceutically acceptable salt of the compound has an application of preparing a medicine for preventing/treating symptoms or diseases such as hyperglycemia and type-2 diabetes.